Background. Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome.
directly-observed 3HP vs daily self-administered 9H [1] . Early in the trial there were reports of possible drug hypersensitivity or flu-like syndrome. This had not been reported with rifapentine plus isoniazid for the treatment of active tuberculosis [5, 6] . A "flu-like syndrome" characterized by fever, chills, fatigue, malaise, headache, myalgia, and arthralgia has been reported with intermittent, high doses of rifampin [7] [8] [9] [10] [11] [12] [13] [14] . Among persons receiving once-weekly rifampin as part of their antituberculosis regimen, a flu-like syndrome developed among 35%-57% of persons who received 1200-1800 mg of rifampin, 22%-31% of those who received 900 mg, and 10% of those who received 600 mg rifampin once-weekly [11] . In contrast, among persons treated with twice-weekly rifampin plus isoniazid, flu syndrome was reported in 8% of those receiving 900 mg and 4% of those receiving 600 mg rifampin [11] .
The rifampin flu-like syndrome usually develops after 3-6 months of treatment [11, 15] .It may be less common in patients who initially have lower, daily dosing [5, 12, 16, 17] . Patients who develop the syndrome on high-dose intermittent regimens often subsequently tolerate lower daily dosing [15] . This is different from the severe immunologically-mediated reaction to other drugs, which typically occurs within 2 months, is less dependent on dose, and often intensifies with continued and subsequent exposure following a reaction [18, 19] . Symptoms with rifampin appear 1-2 hours after drug administration and last up to 8 hours [9, 11] . These symptoms are more common in women than men, and the incidence increases with age [20] [21] [22] .
There have also been case reports of a flu syndrome with isoniazid [23] [24] [25] [26] [27] [28] [29] . Manifestations include pruritic rash, appetite loss, myalgia, arthralgia, fatigue, weight loss, malaise, headache, fever, red eyes, leukocytosis, and hypotension.
We sought to evaluate reactions with systemic manifestations in all participants in the PREVENT Tuberculosis clinical trial, to ascertain their severity, and to identify risk factors for these reactions.
METHODS

Study Population
The PREVENT Tuberculosis study was a prospective, openlabel, randomized trial of 3 months of once-weekly rifapentine 900 mg (graduated dosing for persons ≤50 kg) plus isoniazid 15-25 mg/kg (rounded up to nearest 50 mg; 900 mg maximum) given under direct observation (3HP), compared to 9 months of daily self-administered isoniazid 5-15 mg/kg (rounded up to nearest 50 mg; 300 mg maximum) (9H). Persons ≥12 years of age with latent M. tuberculosis infection were enrolled between June 2001 and February 2008. Participants from one PREVENT Tuberculosis study site were excluded from this analysis due to discrepancies regarding receipt of study drug and directlyobserved therapy. The PREVENT Tuberculosis study and a dedicated substudy were approved by the institutional review boards of the Centers for Disease Control and Prevention (CDC) and all study sites. Written informed consent was obtained from all study participants.
Information about adverse events (AE) was collected monthly during treatment and until 30 days after last study dose, graded by the Cancer Therapy Evaluation Program common toxicity criteria [30] . All AE from patients who received ≥1 dose of study drug were included in this analysis. Details have been published previously [1] . All AE, excluding pregnancies and dosing errors, were evaluated. The events were classified as attributed to study drugs (definitely, probably, or possibly) or not-attributed to study drugs (unlikely, non-related, or unclassifiable), as reported by the local site investigator (Supplementary Table 1 ). To focus on clinically significant systemic reactions, isolated hepatotoxicity, isolated rash, AE with known non-drug cause, AE of grade 1 severity [30] , and events in participants able to complete treatment (11 doses in the 3HP arm or 240 doses in the 9H arm), were excluded. The Naranjo adverse drug reaction probability scale [31] was used to objectively evaluate AE regardless of regimen. The scale was modified to increase specificity for possible hypersensitivity events (Supplementary Table 2 ). AE with low score (≤5) were excluded. In addition, after the first AE reports of possible hypersensitivity had been received and no clear definition was available, the PREVENT Tuberculosis sub-study protocol team established two broad criteria for such a drug reaction; (1) hypotension (systolic blood pressure <90 mm Hg), urticaria (hives), angioedema, acute bronchospasm, or conjunctivitis (red eyes); and (2) >4 of the following symptoms occurring concurrently (>1 of which had to be grade 2 or higher): weakness, fatigue, nausea, vomiting, headache, fever, aches, sweats, dizziness, shortness of breath, flushing, or chills. AE that met either of the above criteria were termed systemic drug reactions (SDR).
Severe AE were defined as those resulting in hospitalization, hypotension (systolic blood pressure <90 mm Hg) or loss of consciousness, anaphylaxis, or grade 4 toxicity [30] . Anaphylaxis was defined as at least one major dermatological reaction and at least 1 cardiovascular and/or respiratory criterion [32] .
SDR were classified in one of five hierarchical and mutually exclusive categories: cutaneous, flu-like, gastrointestinal, respiratory, or not defined (see Table 2 for definitions) [13, 15] . Concomitant medications received before or up to 7 days after the SDR (the latter to ensure capture of medications received prior to the event) were recorded and coded according to the WHO Drug B2 Herbal / DDE drug dictionary (June 2010 version). Vitamins, calcium carbonate, mineral supplements, and antioxidants were considered nonstudy concomitant medications and included in the analysis. Medications given to treat AE were not considered concomitant medications. An in-depth study record review was performed (by R. M., E. P., G. S., N. F. A., M. E. V.) for all AE attributed to study drugs. Drug rechallenge was allowed at the discretion of the site study investigators (See guidelines for re-challenge in the Supplemental Material, including Figure 1 ). Drug restart was defined as receipt of the full protocol-recommended regimen after the event.
Statistical Analysis
Categorical variables were compared using the Pearson's chisquared test. Continuous variables were compared using the 2-sample Kolmogorov-Smirnov (asymptotic) nonparametric b Criteria for possible hypersensitivity: (1) hypotension (systolic blood pressure <90 mm Hg), urticaria, angioedema (defined as swelling around the lips or eyes), acute bronchospasm, or conjunctivitis (red eyes); or (2) ≥4 of these symptoms concurrently, ≥1 of which was grade 2 or higher: weakness, fatigue, nausea, vomiting, headache, fever, aches, sweats, dizziness, shortness of breath, flushing, or chills; c Severe Adverse Event: hospitalization, hypotension (systolic blood pressure <90 mmHg) or loss of consciousness, anaphylaxis, or grade 4 toxicity. These categories were not mutually exclusive; d 3HP: 3 months of once-weekly rifapentine plus isoniazid given under direct observation; e 9H: 9 months of daily isoniazid given self-administered; f One report was received after the 6 cases of hypotension reported in the parent PREVENT Tuberculosis study. Abbreviation: ADR, adverse drug reaction.
test [33] . Univariate and multivariate logistic regression analyses were performed; clinically important variables (HIV infection and smoking) and all variables with P < .05 in the univariate analysis were included in the multivariate model. Interaction terms between study arms and all factors were also included in the multivariate model; this analytical strategy reveals whether arm-specific associations are statistically different between arms; this comparison is not possible in stratified analysis [34] . To control for variations among enrolling sites, we constructed a generalized linear mixed model where each site was treated as a random effect [35] . In addition, an analysis of residuals was used to analyze age as a continuous variable; no pattern was identified, so median age of the study population was used in the model. Body mass index (BMI) was evaluated as a continuous variable but grouped according to standard categories [36] . A cluster analysis clustered participants with similar signs and symptoms (Supplemental Material) [37] . A nonparametric test compared the time of SDR onset after the last dose ingested, and the time to resolution. Statistical analyses were conducted using SAS version 9.3; the cluster analysis was performed using R.
RESULTS
Among the 7552 (3HP = 3893 and 9H = 3659) study participants who received ≥1 dose of study drug, there were 1520 AE reported. After excluding pregnancies (n = 117) and dosing errors (n = 68), 809 were reported as nonattributed and 526 attributed to study drugs. No SDR were identified in the nonattributed group, although 6 events could not be evaluated due to limited data. Of 526 AE attributed to study drugs, 153 SDR occurred in 153 individual participants (2.0% of all 7552 participants): 138/3893 (3.5%) in the 3HP arm vs 15/3659 (0.4%) in the 9H (P < .001) ( Figure 1 and Table 1 ). There were 14 severe SDR, of which 13 occurred in the 3HP arm (13/3893 = 0.3%).
Among the 138 events in the 3HP arm, 23 (17%) were cutaneous and 87 (63%) were flu-like syndrome. In contrast, among the 15 events in the 9H arm, 9 (60%) were cutaneous and 2 (13%) were flu-like (Table 2) . Of the 138 participants in the The syndromes were compiled from definitions in the literature and the study protocol.
The syndromes were hierarchically ordered (as presented below) and mutually exclusive. a Angioedema, urticaria, rash and itching, or anaphylaxis (defined as cutaneous plus circulatory or respiratory reaction) that occurred within 24 hours of the study dose. b Presence of (fever or chills) and (weakness, fatigue or muscle pain) and (aches, syncope, heart rate >100, palpitations, flushing, dizziness, conjunctivitis (red eyes), or sweats). This includes 6 syncope events. c Presence of vomiting (with or without nausea) or abdominal pain.
d Bronchospasm, cough, shortness of breath, or chest pain.
e Did not meet any of the above definitions.
3HP arm who developed an SDR, 73 were re-challenged with study drug (Supplementary Table 3 ). Of the 51 participants initially rechallenged with rifapentine, 36 (71%) tolerated it. Of the 20 participants initially rechallenged with isoniazid, 3 (15%) tolerated it. Only 2/73 (3%) tolerated both isoniazid and rifapentine on re-challenge, and none completed study treatment. In addition, none of the 153 study participants who developed an SDR completed study treatment, per study criteria. Data on whether an alternative regimen was completed were not available.
Persons developing an SDR were more likely to receive 3HP, were older, more likely to be female, of white non-Hispanic race/ethnicity, and to receive concomitant nonstudy medication (Supplementary Table 4 ). Among persons developing an SDR, the event occurred after a median of 3 once-weekly doses in the 3HP arm and 16 daily doses in the 9H arm (Table 3 ). In the 3HP arm, the median time from drug ingestion to symptom onset was 4 hours, and the median time from symptom onset to resolution was 24 hours (Table 3 ). There was no difference in time to symptom resolution among those who did vs did not develop fever (data not shown).
Signs and symptoms of the SDR are in Supplementary  Table 5 . In the 3HP arm, fatigue, headache, nausea, weakness, chills, and myalgia were most common. All of the signs and symptoms were associated in the cluster analysis, distinct from a cluster that included rash and itching. Fever (>100°F) was present in approximately half.
There were 3 persons younger than 18 (age range 14-17): 2 received 3HP and 1 received 9H; none developed a severe event and all recovered in <24 hours.
The univariate and multivariate logistic regression analysis of risk factors for SDR are in Tables 4 and 5 . In the multivariate There were 153 systemic drug reactions among 7552 study participants.
There was no interaction between age and receipt of concomitant nonstudy drugs.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio. a Of the 7552 study participants. There were 153 systemic drug reactions among 7552 persons.
The model also included HIV infection and smoking because of their potential role in systemic drug reactions, but these variables were not statistically significant. We tested for the following possible individual interactions: a) regimen with race, sex, age, concomitant medications, BMI, HIV, smoking; b) concomitant medications with race, sex, and age. The only interaction was between regimen and sex, therefore the results (Table 6 ) are presented for each category of regimen and sex.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio. a Of the 7552 study participants.
analysis, factors independently associated with these reactions were receipt of 3HP, white race, female sex, age ≥35 years, and lower BMI. To control for variations according to study site, a generalized linear mixed model was performed; results were similar (data not shown). In the multivariate analysis, an interaction between regimen and sex was noted; the risk of SDR according to regimen and sex is in Table 6 . After adjusting for the variables in the multivariate model, among those receiving 9H, the risk of SDR was 15-fold higher in women than men.
Among those receiving 3HP, the risk of SDR was approximately twice as high in women as men. In those persons at highest risk of SDR (white non-Hispanic women >35 years old who received 3HP), the probability of developing SDR was 12.3% (95% CI, 8.1%, 24.4%) (Supplementary Table 6 ). Severe SDR were uncommon. Among the 13 persons who received 3HP and developed a severe SDR, the median number of doses received before event onset was 5. Six persons developed hypotension, and 2 others reported syncope. The lowest reported systolic blood pressure was 70 mmHg (in one participant), though none required vasopressor support and the median time to recovery was 24 hours. Overall, 6 persons were reported to develop syncope, of whom 2 had severe SDR; none of them had documented hypotension and all of them recovered in <24 hours. Only one of the 6 episodes of syncope had loss of consciousness.
There were no deaths or permanent sequelae from SDR; there were no instances of Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms, and no episodes of acute renal failure, bleeding due to thrombocytopenia, or hemolytic anemia. There was 1 episode each of thrombocytopenia (without evidence of bleeding), anemia (not hemolytic), and neutropenia (see Supplemental Material for details). There were no reports of renal failure.
In a logistic regression analysis of predictors of clinically severe SDR among persons who received 3HP, white non-Hispanic race/ethnicity and concomitant nonstudy medication were the only statistically significant variables (Table 7) . Of the 14 persons who developed clinically severe SDR, 9 (64%) received ≥2 concomitant medications. Of the 28 concomitant medications received, 14 (50%) were for the alimentary tract/metabolism and 8 (29%) were for cardiovascular indications. There was Of those concomitant medications reported by persons who developed a severe event, 52% were classified as for the alimentary tract/metabolism (including vitamins) and 28% were classified as cardiovascular.
Prior to performing these analyses among persons who received 3HP, the following interactions were evaluated among the full dataset of 7552 participants, but none were statistically significant: (1) regimen with race, sex, age, concomitant medication, BMI; (2) concomitant medication with race, sex, age; (3) BMI with sex.
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio. a Of the 7552 study participants.
no predominant medication or medication class associated with severe SDR. In those persons at highest risk of severe SDR (white non-Hispanic persons who received 3HP plus concomitant medications), the probability of developing SDR was 1.8% (95% CI, .9%, 4%) (Supplementary Table 6 ).
DISCUSSION
In the PREVENT Tuberculosis study SDR were uncommon but occurred significantly more frequently among persons who received 3HP than 9H. Among persons in the 3HP arm, the most common presentation was flu-like syndrome, which accounted for 63% of the SDR episodes. These reactions were associated with female sex, white non-Hispanic race/ethnicity, age ≥35 years old, and lower BMI. Female sex, white race, and increased age have been reported as risk factors for flu-like syndrome among persons who received intermittent rifampinusually at high doses and given together with isoniazid or ethambutol [11, 12, 15, 20, 38] . In 2 recent studies of 3HP for treatment of latent M. tuberculosis infection, there were no reports of flu-like syndrome, but both studies were smaller than PREVENT Tuberculosis and were conducted in Brazil and South Africa; very few white women of older age were enrolled [2, 3] . The inconsistency in reproducibility of symptoms upon single and multiple drug rechallenge, female sex, the association with lower BMI, and the successful completion of treatment in many patients without morbidity despite the previous adverse drug reactions, suggest that the SDR and flu-like symptoms may not be immunologically mediated. This SDR differs from flu-like syndrome associated with immunologically mediated reactions such as with abacavir, where there is significant intensification with continued dosing and severe re-challenge morbidity [19] . However, the possibility of an immune-mediated reaction cannot be ruled out. Previous reports of the rifampin flu-like syndrome noted a possible association with rifampin antibodies [39, 40] . However, the presence of antibodies in persons who have received and tolerated antibiotics is relatively common, and of uncertain importance.
Isoniazid can rarely cause a classic delayed immunologically mediated drug hypersensitivity reaction. Although it can be associated with fever and flu-like symptoms, it can have features distinct from the SDR described in this study, such as skin eruptions, lymphadenopathy, hepatitis, and eosinophilia [23, 24, [27] [28] [29] 41] . Isoniazid can also interact with foods rich in monoamines, particularly tyramine [25, 42, 43] .
Given the similarity of published reports of flu-like syndrome associated with rifampin and the reactions seen in this study, and given the 9-fold greater frequency of such reactions in the 3HP arm, one might expect rifapentine to more likely cause these symptoms than isoniazid. However, rifapentine was better tolerated than isoniazid on rechallenge (Supplementary Table 3 ). In a recent multicenter randomized clinical trial of intermittent continuation-phase therapy after 2 months of daily therapy, participants (64% of whom were black males) received 900 mg rifapentine twice-weekly or 1200 mg rifapentine once-weekly, both in combination with moxifloxacin, pyrazinamide, and ethambutol (not isoniazid). There were no reports of possible hypersensitivity or flu-like syndrome [44] (Amina Jindani, unpublished data), but it is possible that the lack of flu-like syndrome was due to the regimens or the population studied.
There were 14 patients with clinically severe reactions: 13/3893 (0.3%) in the 3HP arm and 1/3659 (0.03%) in the 9H arm. Among the 13 episodes in the 3HP arm, 4 patients were hospitalized and 6 developed hypotension. However, most recovered within 24 hours without sequelae. Basic data (onset date, seriousness, attribution) on all AE in the PREVENT Tuberculosis study were collected systematically and prospectively; however, additional data (eg, symptoms on rechallenge, vital signs) were retrospectively and not uniformly collected for severe SDR. This could have contributed the lack of reports of hypotension among those with reported syncope. Decisions regarding rechallenge in participants with SDR were made by the site investigator. About half of participants with an SDR, including the severe events, were not rechallenged. Therefore, it is difficult to ascertain whether isoniazid, rifapentine, or their combination was the cause of SDR. We were also unable to determine whether there were early clinical predictors of subsequent SDR, including severe reactions, since symptoms of adverse drug reactions were ascertained monthly, and the median time to onset in the 3HP arm was before the first monthly visit (week 3). Whether particular symptoms predict subsequent SDR, and discontinuation of treatment in persons with such symptoms decreases SDR risk merits further investigation. It would also appear that SDR would not be mitigated by directly observed therapy, because the median time to symptom onset was 4 hours, and the healthcare worker would likely not be present at that time.
Clinically severe SDR were associated with receipt of 3HP, concomitant nonstudy medications, and white non-Hispanic race/ethnicity. These associations merit further investigation. Although half of the patients received concomitant medications, we found no association with receipt of a particular medication or medication class.
There were several limitations of this study. First, it was a post hoc analysis of data collected in an open-label clinical trial. It is difficult to know if the open label design led to under-or overestimation of endpoints. Additional data on severe SDR were not systematically collected on all study participants specifically related to possible flu-like syndrome. Second, there was no case definition for this syndrome at the start of the study. However, a case definition was developed during the trial, after the first reports of flu-like syndrome were identified. Third, drug levels that correlate with drug exposure were not obtained in this study. Fourth, the data instruments for surveillance of AE in the clinical trial were not well-suited to investigate potentially novel clinical syndromes.
In conclusion, SDR in the PREVENT Tuberculosis study occurred primarily among persons who received 3HP, were mostly flu-like, did not meet objective drug hypersensitivity criteria, and had features that differ from severe immunologically mediated drug reactions. Most SDR were mild and resolved within 24 hours. Attribution to rifapentine or isoniazid separately or together is not possible with the available data, though the syndromes observed were similar to those reported previously with rifampin. Persons of white race, female sex, increased age, and lower BMI were at increased risk. Severe reactions were rare and appeared to be associated with the receipt of concomitant medication and white race. As 3HP is introduced into clinical practice, including populations that differ from our study population, clinical monitoring and continued vigilance for SDR are warranted.
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